Factors affecting mobility: multivariate analyses

Las características de las proteínas MVIIA y EETI-II permiten la mutación de su secuencia de aminoácidos en una región que no interactúa con el resto de la miniproteína, sin modificar su estructura radicalmente. Las regiones de interacción identificadas de la ebvIL-10 con su receptor, contienen la longitud adecuada para ser introducidas en nuestras miniproteínas andamio. Con el diseño y modelado de las proteínas mutantes, se obtuvieron seis proteínas específicas para analizar médiate Docking. El refinamiento por dinámica molecular de las proteínas mutantes nos permitió conocer un aproximado de la estructura y el acomodo especial de los aminoácidos en cada una de ellas. El análisis de acoplamiento molecular realizado a cada una de las miniproteínas mutantes muestra a los diseños MVIIA_L1 y EETI_L1 como potenciales inhibidores de la ebvIL-10. El siguiente paso de este trabajo debería ser la validación in vitro e in vivo de los diseños realizados en este trabajo. La presente tesis permite concluir en base a los cálculos computacionales obtenidos que el método de diseño in silico de proteínas específicas es una opción viable para la creación de potenciales fármacos inhibidores de la ebvIL-10, minimizando el costo de diseño inicial, típicamente realizado mediante experimentación bioquímica.

Lista de referencias

Abbas, A. K., Lichtman, A. H., and Pillai, S. (2012). Inmunología celular y molecular (7a Edición). Barcelona, España: Elsevier.

Ackerman, S. E., Currier, N. V, Bergen, J. M., and Cochran, J. R. (2014). Cystine-knot peptides: emerging tools for cancer imaging and therapy. Expert Review of Proteomics, 11(5), 561–72.

Atkinson, R. A., Kieffer, B., Dejaegere, A., Sirockin, F., and Lefèvre, J. F. (2000). Structural and dynamic characterization of ω-conotoxin MVIIA: The binding loop exhibits slow conformational exchange. Biochemistry, 39(14), 3908–3919.

Chaudhury, S., Lyskov, S., and Gray, J. J. (2010). PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics (Oxford, England), 26(5), 689–91.

Cohen, J. I., Mocarski, E. S., Raab-Traub, N., Corey, L., and Nabel, G. J. (2013). The need and challenges for development of an epstein-barr virus vaccine. Vaccine, 31(SUPPL2), B194–B196.

Couper, K. N., Blount, D. G., and Riley, E. M. (2008). IL-10: The Master Regulator of Immunity to Infection. The Journal of Immunology, 180(9), 5771–5777.

Craik, D. J., Daly, N. L., and Waine, C. (2001). The cystine knot motif in toxins and implications for drug design. Toxicon  : Official Journal of the International Society on Toxinology, 39(1), 43–60.

Cui, X., Cao, Z., Sen, G., Chattopadhyay, G., Fuller, D. H., Fuller, J. T., and Snapper, C. M. (2013). A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine, 31(30), 3039–45.

Daly, N. L., and Craik, D. J. (2011). Bioactive cystine knot proteins. Current Opinion in Chemical Biology, 15(3), 362–8.

Damania, B. (2004). Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nature Reviews. Microbiology, 2(8), 656–68.

Davison, A. J., Eberle, R., Ehlers, B., Hayward, G. S., McGeoch, D. J., Minson, A. C., …

Thiry, E. (2009). The order Herpesvirales. Archives of Virology, 154(1), 171–177. Evans, C. M., Kudesia, G., and McKendrick, M. (2013). Management of herpesvirus

infections. International Journal of Antimicrobial Agents, 42(2), 119–28.

Gracy, J., and Chiche, L. (2010). Optimizing structural modeling for a specific protein scaffold: knottins or inhibitor cystine knots. BMC Bioinformatics, 11(1), 535.

Gracy, J., Le-Nguyen, D., Gelly, J.-C., Kaas, Q., Heitz, A., and Chiche, L. (2008). KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007. Nucleic Acids Research, 36(Database issue), D314–9.

Jagadish, K., and Camarero, J. a. (2010). Cyclotides, a promising molecular scaffold for peptide-based therapeutics. Biopolymers, 94(5), 611–616.

Josephson, K., Logsdon, N. J., and Walter, M. R. (2001). Crystal structure of the IL- 10/IL-10R1 complex reveals a shared receptor binding site. Immunity, 15(1), 35–46. Josephson, K., McPherson, D. T., and Walter, M. R. (2001). Purification, crystallization

and preliminary X-ray diffraction of a complex between IL-10 and soluble IL-10R1. Acta Crystallographica Section D, 57(12), 1908–1911.

Kaplan, A. (1983). The herpesviruses. (B. Roizman, 1ra Ed.) (Vol. 1). Boston, MA: Springer US.

Kofteridis, D. P., Koulentaki, M., Valachis, A., Christofaki, M., Mazokopakis, E., Papazoglou, G., and Samonis, G. (2011). Epstein Barr Virus hepatitis. European Journal of Internal Medicine, 22(1), 73–76.

Kolmar, H. (2008). Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. The FEBS Journal, 275(11), 2684–90.

Kolmar, H., and Christmann, A. (2008). The therapeutic potential of cystine-knot microproteins. Innovations in Pharmaceutical Technology, (26), 34–36.

Krätzner, R., Debreczeni, J. É., Pape, T., Schneider, T. R., Wentzel, A., Kolmar, H., …

Uson, I. (2005). Structure of Ecballium elaterium trypsin inhibitor II (EETI-II): A rigid molecular scaffold. Acta Crystallographica Section D: Biological Crystallography, 61(9), 1255–1262.

Malefyt, R. D. W., Yssel, H., Spits, H., and Vries, J. E. De. (1993). Interleukin-10. Annual Review of Immunology, 314–320.

Mangel and Tyring Stephen, G. (2012). Herpesviridae- A look into this unique family of viruses (1ra ed.). USA: INTECH.

Miller, G., El-Guindy, A., Countryman, J., Ye, J., and Gradoville, L. (2007). Lytic cycle switches of oncogenic human gammaherpesviruses. Advances in Cancer Research, 97(06), 81–109.

Moore, K. W., Malefyt, R. D. W., Robert, L., and Garra, A. O. (2001). Interleukin-10 and the Interleukin-10 Receptor. Annual Review of Immunology, 1, 683–765.

Moore, S. J., Hayden Gephart, M. G., Bergen, J. M., Su, Y. S., Rayburn, H., Scott, M. P., and Cochran, J. R. (2013). Engineered knottin peptide enables noninvasive optical

imaging of intracranial medulloblastoma. Proceedings of the National Academy of Sciences of the United States of America, 110(36), 14598–603.

Moore, S. J., Leung, C. L., Norton, H. K., and Cochran, J. R. (2013). Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PloS One, 8(4), e60498.

Olivera, B. M., Cruz, L. J., de Santos, V., LeCheminant, G. W., Griffin, D., Zeikus, R., …

Gray, W. R. (1987). Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry, 26(8), 2086–2090.

Pimienta, G., Fok, V., Haslip, M., Nagy M., Takyar, S., Steitz, J. A. (2015) Proteomics and Trasncriptomics of BJAB Cells Expressing the Eptein-Barr Virus Noncoding RNAs EBER1 and EBER2. Plos ONE, 10(6): e0124638

Redpath, S., Ghazal, P., and Gascoigne, N. R. J. (2001). Hijacking and exploitation of IL-10 by intracellular pathogens. Trends in Microbiology, 9(2), 86–92.

Reiss, S., Sieber, M., Sandy., Oberle, V., Wentzel, A., Spangenberg, P., Claus, R., Kolmar, R. and Lösche, W. (2006). Inhibition of platelet aggregation by graftingRGDand KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17, 153–157.

Roizman, B., Carmichael, L. E., Deinhardt, F., De-The, G., Nahmias, A. J., Plowrigt, W.,

… Wolf, K. (1981). Herpesviridae Definition, Provisional Nomenclature and Taxonomy. Intervirology, 16, 201–217.

Saraiva, M., and O’Garra, A. (2010). The regulation of IL-10 production by immune cells. Nature Reviews. Immunology, 10(3), 170–81.

Schmidtko, A., Lotsch, J., Freynhagen, R. and Geisslinger, G. (2010). Ziconotide for treatment of severe chronic pain. New Drug Class, 375, 1569-77.

Seifert, H., Jansen, B., and Farr, B. M. (2006). Epstein-Barr Virus. (A. Tselis & H. Jensen, Eds.) (1ra ed.). New York: Tatlor & Francis.

Silverman, A. P., Kariolis, M. S., and Cochran, J. R. (2011). Cystine-knot peptides engineered with specificities for aiIbb3 or aiIbb 3 and avb3 integrins are potent inhibitors of platelet aggregation. Journal of Molecular Recognition, 24(1), 127–135. Thorley-Lawson, D. a. (2005). EBV the prototypical human tumor virus--just how bad is

it? The Journal of Allergy and Clinical Immunology, 116(2), 251–61; quiz 262. Thorley-Lawson, D. a, and Allday, M. J. (2008). The curious case of the tumour virus: 50

Thorley-Lawson, D. A. (2001). Epstein-Barr virus: exploiting the immune system. Nature Reviews. Immunology, 1(October), 75–82.

Webb, B., and Sali, A. (2014). Comparative Protein Structure Modeling Using MODELLER. In Current Protocols in Bioinformatics (Vol. Unit 5.6, p. Supplements 47). Wiley Online Library.

Yoon, S. Il, Jones, B. C., Logsdon, N. J., and Walter, M. R. (2005). Same structure, different function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure (London, England  : 1993), 13(4), 551–64.

Young, L. S., and Rickinson, A. B. (2004). Epstein-Barr virus: 40 years on. Nature Reviews. Cancer, 4(10), 757–68.